Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 87702

Thursday, 12/17/2009 5:55:17 PM

Thursday, December 17, 2009 5:55:17 PM

Post# of 257253
Re: PYMX-SNY/NVS

The commercial benefit of having reversibility data would accrue not only to branded Lovenox, but also to any substitutable generic and vice-versa. Hence, if SNY or NVS sponsored a PMX-60056 program, they would be helping their competitor as much as they would be helping themselves.

But the reversibility could help either branded or generic Lovenox compete against the newer oral anti-coagulants, correct?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now